Author

Jan Murin

Observed name: Jan MURIN

Observed institutions: University Hospital Bratislava, Comenius University Bratislava

OpenAlex ID: A5108756413

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Journal of the American College of Cardiology · 160

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 31

Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial

2024 · C Michael Gibson, Danielle Duffy, et al. · European Heart Journal · 29

Obesity, elevated levels of fasting plasma glucose and type 2 diabetes are associated with aortic stiffness

2023 · Viera KUPCOVA, Jan MURIN, et al. · Bratislavské lekárske listy/Bratislava medical journal · 2

Abstract 10470: Projected Lifetime Benefits of Alirocumab in Patients After Acute Coronary Syndrome

2022 · Andrzej Budaj, Yedid Elbez, et al. · Circulation

Works count: 6

Citation count: 382

H-index: 4

I10-index: 4